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OBJECTIVES: To investigate the trends and characteristics of pethidine prescriptions and users in Taiwan from 2002
to 2007.
METHOD: All pethidine users (n = 3,301,136) in Taiwan from 2002 to 2007 were linked to National Health Insurance
claims to identify pethidine prescriptions. We examined the trends in pethidine user prevalence and the proportion
of pethidine prescriptions according to health care characteristics. A logistic regression model was used to compare
patient demographics and health care characteristics associated with pethidine prescriptions between 2002 and
2007.
RESULTS: Despite the decline in the number of pethidine users and prescriptions over the six-year period, more than
half a million people were prescribed pethidine annually. In fact, an increasing proportion of pethidine
prescriptions were observed in clinics, outpatient settings, and patients who had both operations and cancer
diagnoses. Pethidine prescriptions were mostly associated with a non-operation status without a cancer diagnosis
(.60%). However, approximately 10% of the total pethidine prescriptions were found in patients with a cancer
diagnosis but no operation. Compared to those in 2002, pethidine prescriptions in 2007 were more likely to be
found in people 80 years or older, rural residents, patients from clinics, outpatient settings and operation patients
with cancer diagnoses.
CONCLUSIONS: A population-based survey in Taiwan demonstrated decreasing consumption of pethidine from
2002 to 2007; however, an increased proportion of prescriptions in certain health care settings was observed. In
addition, 10% of the pethidine prescriptions were for cancer patients without operations. These cases need further
evaluation for the determination of appropriate pethidine use.
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INTRODUCTION
Pethidine (meperidine), which has a short duration of
action, has been widely and routinely prescribed for
moderate-to-severe pain in medical and surgical patients
(1,2). Pethidine is a synthetic opioid that was introduced in
1939 for clinical use as an anticholinergic when its analgesic
properties were discovered. It has an active metabolite,
normeperidine (3), which accumulates in the organism
causing stimulation (anxiety, hyperreflexia, myoclonus and
mood changes) and even seizures, and interacts with
monoamine oxidase inhibitor (MAOI) drugs causing com-
plications such as serotonergic crisis (3-6). These adverse
effects become evident if multiple doses are given over a
period of time (3-5). In addition, adverse reactions to
normeperidine can occur in patients with normal renal
function if the administered doses are sufficiently high (4).
In addition, the once-purported theoretical advantages of
pethidine over morphine for patients with cholecystitis or
pancreatitis have also been challenged (7). Consequently, as
awareness of pethidine’s adverse effects has increased,
updated pain management protocols have called for its
cautious use (3). The Agency for Health Care Policy and
Research’s recommendation suggests that oral pethidine
should not be used for pain management and strongly
recommends that parenteral pethidine be restricted to
patients who have a true allergy or intolerance to other
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opioids, in which case it should only be used in acute pain
situations for brief courses (8).
Despite the clinical guidelines that have been issued
against pethidine use in many nations (9), it continues to be
used in many parts of the world, including Taiwan (10-13).
One of the arguments supporting the use of pethidine is that
concurrent analgesics given with pethidine can achieve
adequate analgesia without causing adverse effects in
patients with renal failure (14). Moreover, pethidine was
found to produce fewer side effects than morphine when
used for short-term periods (15). Therefore, pethidine is still
a frequently ordered opioid analgesic, especially for patients
who receive shorter courses of narcotics (2,6).
Due to its habit-forming potential, serotonergic crisis risk
and normeperidine toxicity, the consumption of pethidine
is decreasing worldwide. A population-based study was
conducted in Taiwan to describe the trends in the consump-
tion of opioid analgesics from 2002 to 2007, and the report
indicated that the consumption of transdermal fentanyl and
oral morphine increasedmarkedly over the study period (16).
Although pethidine use decreased gradually, it was pre-
dominantly prescribed to patients without cancer diagnoses
(16). Taiwan recently launched the ‘‘Physician Guidelines on
Clinical Use of Pethidine’’ in September 2011 (17) to limit the
clinical use of pethidine; however, there is no population-
based evidence of pethidine prescriptions available for
Taiwan and other nations. In addition, pethidine is currently
the only available strong opioid in Taiwan for those with
intolerable side effects from morphine or fentanyl. We
therefore conducted this population-based study using data
from National Health Insurance (NHI) claims to investigate
the trends and characteristics of pethidine prescriptions and
users in Taiwan from 2002 to 2007.
MATERIALS AND METHODS
Source of data
The data analyzed in this study were retrieved from the
National Health Insurance Research Database (NHIRD)
provided by the Bureau of National Health Insurance
(BNHI) (18). Taiwan reformed its insurance programs into
the universal National Health Insurance (NHI) system in
1995, and more than 99% of residents in Taiwan were
enrolled in the NHI program in 2007 (18). This NHI research
database contains registration files and original claim data
for reimbursements and offers information on each patient’s
characteristics, diagnosis, treatments, prescriptions, and
associated ambulatory and inpatient medical benefit claims.
The database also protects the privacy and confidentiality of
all beneficiaries and only transfers health insurance data to
health researchers after ethical approval has been obtained.
For the current analysis, we used all pethidine prescrip-
tions issued in outpatient and inpatient claims from 2002 to
2007. All NHI datasets can be interlinked with each
individual’s personal identification number (PIN). The
research protocol for this analysis was ethically approved
by the Review Committee of the National Health Research
Institutes.
Study subjects and measurements
This is a descriptive study that depicts secular trends and
characteristics of pethidine prescriptions and users in
Taiwan from 2002 to 2007. During the study period, a total
of 3,380,884 prescriptions, of which 99.1% and 0.9% were
injections (drug code: A005874209) and tablets (drug code:
A005858100), respectively, were written for 3,301,136
patients. From each prescription claim, we retrieved
information on the patient’s date of birth, gender, the
urbanization level of the patient’s residential area, the
medical institution’s accreditation level (clinic, local, regio-
nal hospital, or medical center), the setting (hospital,
outpatient, or emergency department), and the patient’s
operation status and cancer diagnosis status. The age of
each patient was calculated as the difference between the
date of the prescription and the date of birth. The
urbanization level for each of the 365 townships in Taiwan
was categorized (i.e., urban, suburban, or rural) according to
the National Statistics of Regional Standard Classification
(19). Outpatient claims provided one procedure code and
up to three diagnostic codes for each ambulatory care visit.
Inpatient claims included up to five codes for procedures
and diagnoses separately. All codes are based on the
International Classification of Diseases codes, 9th version
Clinical Modification (ICD-9-CM). Operation status was
determined by the entry of any procedure code of ICD-9-
CM except for obstetrical procedures [72-75], miscellaneous
diagnostic and therapeutic procedures [87-99], and diag-
nostic procedures (Appendix). Any claims accompanied by
primary or secondary diagnoses of malignancy (140-209,
230-239) were classified as a cancer diagnosis.
The amount of pethidine prescriptions was expressed as
the defined daily dose (DDD) per 1,000 inhabitants per day
(20). The DDD is a technical unit of measurement,
established by an expert panel as the assumed average
maintenance dose when the drug is used for its main
indication by an adult, and it is based on the Anatomical
Therapeutic Chemical (ATC) classification index (20). The
following formula was used in this analysis:
Number of DDD/1,000 inhabitants/day = (number of
packages dispensed 6 number of doses per package 6
number of mg per dose) / (DDD in mg6 number of 1,000
inhabitants in the mid-year population6 365 days).
The DDD value of pethidine is 400 milligrams (20). The
mid-year population for each year of the study period was
obtained from the Ministry of the Interior of Taiwan (21).
Data analysis
We first described the secular trends for the annual
numbers of pethidine users, total prescriptions, total
amounts, and DDD/1,000 inhabitants/day according to
the forms of pethidine (i.e., injections or tablets). We then
calculated the prevalence rate of pethidine users for each
year. We also calculated the proportion of total pethidine
prescriptions each year according to selected health care
characteristics. To further compare patient demographics
and health care characteristics for all pethidine prescrip-
tions between 2002 and 2007, we performed simple and
multiple logistic regression models, with a generalized
estimation equation accounting for clustering of prescrip-
tions administered to the same patient. The odds ratio (OR)
of receiving a pethidine prescription in 2007 in relation to
the selected patient demographics and health care char-
acteristics was estimated. In addition, we calculated the
distribution of the proportion of pethidine prescriptions
across primary diagnoses based on ICD-9-CM diagnostic
codes in non-operation patients over the six-year period.
All statistical analyses were performed with SAS (version
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9.2; SAS Institute, Cary, NC). P values ,0.05 were
considered statistically significant.
RESULTS
Pethidine was prescribed to more than 500,000 people
annually for pain relief from 2002 to 2007 (Table 1); the
numbers of pethidine users and total prescriptions
decreased slightly, by 4.1% and 4.6%, respectively. The
DDD/1,000 inhabitants/day decreased from 0.027 to 0.022,
representing a reduction of 18.5%; this decreasing trend was
more obvious for tablets than for injections.
Table 2 shows the prevalence rate of pethidine users
during the study period. The overall prevalence rate of
pethidine users was 24.9 per 1,000 people in 2002; it
increased slightly in 2004, and then declined gradually in
2007, representing a 6.4% decrease over the study period.
However, pethidine use increased with age, especially in
those over 80 years old. Males had a higher prevalence than
females. Additionally, there was an apparent geographic
variation in the prevalence of pethidine use; people living in
rural areas had a higher prevalence rate of pethidine use
than in urban areas. We also noted that the subgroups with
higher prevalence rates of pethidine users tended to have a
smaller percentage of reduction in the prevalence over the
study period. People over 80 years old, males and those
from rural areas all experienced small reductions in
prevalence at 2.9%, 2.1% and 1.3%, respectively. However,
the largest reduction in the prevalence of pethidine users
was among people under 40 years old (15.0%-16.0%); the
corresponding figures for females and urban residents were
8.0% and 9.6%, respectively.
Table 3 illustrates the distributions of pethidine prescrip-
tions across various health care characteristics. Medical
centers accounted for the largest proportion of prescrip-
tions; however, these prescriptions decreased by 9.6% from
Table 1 - Numbers of pethidine users, total prescriptions, total amounts, and defined daily dose, 2002-2007.
Calendar year
Percent change
2002 vs. 2007
2002 2003 2004 2005 2006 2007
Injections
No. of users 553,364 527,054 560,044 550,979 546,515 533,776 -3.5
Total prescriptions 568,389 543,070 571,415 563,129 559,779 545,581 -4.0
Total amount
(mg6106)
79 77 77 76 74 69 -12.7
DDD/1,000/day 0.024 0.023 0.023 0.023 0.022 0.021 -12.5
Tablets
No. of users 6,283 6,106 6,461 4,772 2,870 2,912 -53.7
Total prescriptions 6,317 6,141 6,479 4,781 2,883 2,920 -53.8
Total amount
(mg6106)
8 9 7 3 3 4 -50.0
DDD/1,000/day 0.003 0.003 0.002 0.001 0.001 0.001 -66.7
Total
No. of users 559,647 533,160 566,505 555,751 549,385 536,688 -4.1
Total prescriptions 574,706 549,211 577,894 567,910 562,662 548,501 -4.6
Total amount
(mg6106)
87 86 84 79 77 73 -16.1
DDD/1,000/day 0.027 0.026 0.025 0.024 0.023 0.022 -18.5
DDD/1,000/day = defined daily dose (DDD) per 1,000 inhabitants per day.
Table 2 - Prevalence rate of pethidine users, 2002-2007.
Variables
2002
(n= 559,647)
2003
(n= 533,160)
2004
(n= 566,505)
2005
(n= 555,751)
2006
(n =549,385)
2007
(n= 536,688)
Percent change
2002 vs. 2007
Age
,18 5.6 4.9 5.3 5.2 5.0 4.7 -16.0
18-40 22.7 22.1 23.3 21.3 20.3 19.3 -15.0
41-64 33.3 31.3 33.4 32.0 31.3 30.0 -9.9
65-79 58.5 54.9 58.9 56.4 55.7 53.8 -8.1
$80 66.3 64.4 68.3 65.9 66.4 64.4 -2.9
Gender
Male 26.2 26.0 28.0 26.9 26.5 25.6 -2.1
Female 22.9 21.0 23.2 22.2 21.7 21.1 -8.0
Urbanization
Urban 22.7 21.5 23.4 21.8 21.4 20.5 -9.6
Satellite 24.2 22.6 24.2 23.0 22.7 21.8 -9.9
Rural 30.0 29.0 31.3 30.6 30.1 29.7 -1.3
Total 24.9 23.9 25.8 24.5 24.1 23.3 -6.4
Incidence density: Per 1,000 people.
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2002 to 2007. Although the proportion of pethidine
prescriptions for clinics was small (,2%), it showed a
substantial increase (19.7%). More than 70% of pethidine
prescriptions were given in inpatient settings; and 61.9% to
63.4% of pethidine was prescribed to non-operation patients
without cancer diagnoses. Despite that, the proportion of
prescriptions for inpatient settings and for those non-
operation patients without cancer diagnoses decreased by
4.1% and 1.5%, respectively. However, pethidine prescrip-
tions from outpatient settings that were administrated to
operation patients with cancer diagnoses demonstrated
notable increases in proportion, at 20.1% and 22.7%,
respectively.
The patient demographics and health care characteristics
for pethidine prescriptions between 2002 and 2007 are
shown in Table 4. Pethidine prescriptions tended to be
administered more to older people in 2007. Compared to
those prescribed in 2002, the pethidine prescribed in 2007
was 1.27 times and 1.77 times more likely to be administered
to patients aged 65 to 79 years and greater than 80 years,
respectively. Additionally, pethidine was more likely to be
prescribed to patients living in rural areas (OR= 1.09, 95%
confidence interval (CI) = 1.08-1.10) in 2007. With respect to
the health care characteristics, compared to the 2002
prescriptions, the prescriptions in 2007 were more likely to
be obtained in clinics (OR= 1.48, 95% CI = 1.43-1.54) and
outpatient settings (OR= 1.27, 95% CI = 1.26-1.29), as well as
in operation patients with a cancer diagnosis (OR= 1.24,
95% CI = 1.22-1.27).
Because non-operation patients without cancer diagnoses
accounted for more than 60% of the total prescriptions, we
further examined the leading diagnosis associated with
these prescriptions. We noted that the top five leading
diagnoses of disease included kidney and ureter calculus
and other symptoms involving the abdomen and pelvis,
such as abdominal pain, pancreatic diseases, hemorrhoids,
and acute appendicitis; these causes accounted for 23.48% of
all prescriptions (Table 5). In addition, we also noted that
approximately 10% of pethidine prescriptions were admi-
nistered to non-operation cancer patients, which is usually
considered to be inappropriate. The top five cancer
diagnoses with non-operation status included malignant
neoplasm of the liver and intrahepatic bile ducts, malignant
neoplasm of the colon, malignant neoplasm of the trachea,
bronchus and lung, malignant neoplasm of the rectum, recto
sigmoid junction, and anus, and malignant neoplasm of the
female breast (Table 5).
DISCUSSION
This is the first national study to analyze the trends and
characteristics of pethidine use in Taiwan. Although there
were declining trends in the prevalence of pethidine users,
total prescriptions and DDD/1,000 inhabitants/day in
Taiwan over the study years, there were still more than
500,000 people who received pethidine prescriptions for
pain each year, representing 2.4% of the total population of
Taiwan. Additionally, older people, males and people living
in rural areas showed a smaller reduction in the prevalence
rate of pethidine users than the national average (6.4%).
Moreover, there was an increasing proportion of pethidine
prescriptions from clinics, outpatient settings and operation
patients with cancer diagnoses. We noted that pethidine
prescriptions were mostly found in non-cancer patients
(85%). However, 10% of the total pethidine prescriptions
were found in non-operation patients with a cancer
diagnosis, and these prescriptions should be evaluated for
their appropriateness.
The decreasing trend in pethidine use noted in Taiwan is
consistent with previous reports from other nations
(11,12,22-24). Joranson et al. (23) retrospectively surveyed
the U.S. medical record database, which revealed a 35%
decrease (5.2 to 3.4 million grams) in the medical use of
pethidine from 1990 to 1996. Gilson et al. (22) also used the
same database to demonstrate that there was a further decline
in medical use of pethidine by over 6% (5.8 to 5.4 million
grams) from 1997 through 2002. Additionally, in Israel from
2000 to 2008, pethidine consumption fell by 65%, from 0.07 to
0.02 DDD/1,000 inhabitants/day (12). However, two popula-
tion-based surveys found that pethidine consumption was
less than 0.01 DDD/1,000 inhabitants/day and remained
constant in both Spain between 1992 and 2006 (11) and in the
Slovak Republic between 1998 and 2002 (24). The fall in
pethidine consumption in recent years may reflect the
campaign by major authorities towards a decrease in regular
and long-term use of pethidine. This decrease may also
signify the growing awareness of pethidine’s shortcomings,
including its short duration of action and conversion to a
long-lasting toxic metabolite (4). Moreover, multifaceted
Table 3 - Proportion of total pethidine prescriptions according to health care characteristics, 2002-2007.
Variables
2002
(n= 574,706)
2003
(n= 549,211)
2004
(n = 577,894)
2005
(n= 567,910)
2006
(n= 562,662)
2007
(n = 548,501)
Percent change
2002 vs. 2007
Accreditation level
Medical center 47.4 45.6 45.3 43.9 45.0 42.8 -9.7
Regional hospital 36.0 36.6 36.8 38.4 38.5 41.4 15.1
Local hospital 15.7 16.7 16.3 15.9 15.2 14.7 -6.6
Clinic 1.0 1.1 1.6 1.8 1.4 1.2 19.7
Patient setting
Inpatient 73.6 71.8 73.2 71.7 71.0 70.6 -4.1
Outpatient 10.9 11.8 12.6 13.5 13.1 13.1 20.1
Emergency department 15.5 16.4 14.2 14.8 15.9 16.3 5.1
Operation/Cancer status
Operation
With cancer diagnosis 4.4 4.7 5.0 5.2 5.4 5.4 22.7
Without cancer diagnosis 22.0 21.6 22.6 23.0 22.7 22.4 2.2
Non-operation
With cancer diagnosis 10.2 10.5 10.2 9.8 10.0 9.7 -5.4
Without cancer diagnosis 63.4 63.3 62.3 62.0 61.9 62.5 -1.5
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education, combining a pethidine formulary restriction and a
computerized provider order entry regulation initiative, has
also minimized pethidine prescriptions (25-27). Furthermore,
restricting the use of pethidine to patients who are allergic to
or unable to tolerate all other opioids has been advocated in
Taiwan as well as in many other countries worldwide (3,12).
Despite a decrease in the prevalence of pethidine use, our
study reveals an increased number and proportion of
pethidine users aged 80 years and older. Similar increases
in number and proportion were also noted in pethidine
prescriptions in operation patients with cancer diagnoses, as
well as in those from rural areas, regional hospitals, clinics,
Table 5 - Leading diagnoses associated with pethidine prescriptions for non-operation patients with and without cancer
diagnoses, 2002-2007.
Rank ICD-9-CM
Prescription for non-
operation without cancer
diagnosis
(n = 2,115,366) ICD-9-CM
Prescription for non-
operation with
cancer diagnosis
(n = 339,816)
% %
1 592-Calculus of kidney and ureter 8.99 155-Malignant neoplasm of liver and
intrahepatic bile ducts
16.37
2 789-Other symptoms involving abdomen and
pelvis
4.26 153-Malignant neoplasm of colon 5.97
3 577-Diseases of pancreas 3.88 162-Malignant neoplasm of trachea,
bronchus and lung
5.18
4 455-Hemorrhoids 3.28 154-Malignant neoplasm of rectum,
rectosigmoid junction, and anus
4.70
5 540-Acute appendicitis 3.07 174- Malignant neoplasm of female breast 4.18
Total 23.48 36.40
ICD-9-CM: International Classification of Diseases codes, 9th version Clinical Modification.
Table 4 - Comparisons of the demographics and health care characteristics of patients who received pethidine
prescriptions between 2002 and 2007.
Variables Pethidine prescriptions Crude estimate Adjusted estimate
in 2002
(Controls)
in 2007
(Cases)
n n OR 95% CI OR 95% CI
Demographics
Age (years)
,18 30,849 23,685 reference reference
18-40 209,079 169,413 1.06 1.04-1.08 1.04 1.02-1.06
41-64 206,909 217,571 1.37 1.35-1.39 1.32 1.29-1.34
65-79 102,193 102,205 1.30 1.28-1.33 1.27 1.24-1.29
$80 25,676 35,627 1.81 1.77-1.85 1.77 1.73-1.81
Gender
Male 307,001 299,759 1.02 1.01-1.03 1.00 0.99-1.01
Female 259,357 248,741 reference reference
Urbanization
Urban 228,234 211,054 reference reference
Satellite 161,113 151,828 1.02 1.01-1.03 1.02 1.01-1.03
Rural 185,359 185,619 1.08 1.07-1.09 1.09 1.08-1.10
Health care characteristics
Accreditation level
Medical center 272,180 234,568 reference reference
Regional hospital 206,631 227,008 1.28 1.26-1.29 1.28 1.27-1.29
Local 90,224 80,448 1.03 1.02-1.05 1.05 1.03-1.06
Clinic 5,671 6,477 1.33 1.28-1.37 1.48 1.43-1.54
Patient setting
Inpatient 422,710 387,078 reference reference
Outpatient 62,727 71,907 1.25 1.24-1.27 1.27 1.26-1.29
Emergency department 89,269 89,516 1.10 1.08-1.11 1.12 1.11-1.13
Operation/Cancer status
Operation
With cancer diagnosis 25,322 29,647 1.25 1.22-1.27 1.24 1.22-1.27
Without cancer diagnosis 126,202 123,102 1.04 1.03-1.05 1.08 1.07-1.09
Non-operation
With cancer diagnosis 58,706 53,020 0.96 0.95-0.97 0.90 0.89-0.91
Without cancer diagnosis 364,476 342,732 reference reference
Total 574,706 548,501
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outpatient settings and emergency departments. Elderly
patients usually have higher risks of suffering from both
acute and chronic pain (28). Valano et al. (29) conducted a
cross-sectional study and reported that the majority of
patients treated with opioids were aged 41 to 65 years,
which is similar to our findings. A population-based study
indicated that patients aged 80 years and older who
received care in clinics tended to be prescribed potentially
inappropriate medications (30). Previous studies also
reported that pethidine was administered to only approxi-
mately one in eigth older surgical patients (10), mainly due
to the greater likelihood that the elderly would experience
side effects from pethidine, which may have affected
physician prescribing behavior (31). The increased number
and proportion of elderly pethidine users in recent years
noted in our study warrants further intervention to
effectively reduce the use of pethidine in this vulnerable
population.
The geographic and medical institutional variations in
pethidine use might be due to varying barriers of access to
healthcare. Sadowski et al. (32) conducted a cross-sectional
population-based study to describe accessibility and inten-
sity of analgesic use among older Manitobans by region. The
age- and sex-standardized accessibility and intensity mea-
sures revealed that the highest overall analgesic use
occurred in the most rural/remote regions of the province.
Valano et al. (29) used a cross-sectional study design to
demonstrate that adherence to analgesic treatment guide-
lines was higher in large hospitals than in medium- and
small-sized hospitals. A recent study also reported that
pethidine was prescribed to 7.6% and 4.3% of all study
patients at a large private tertiary care teaching hospital and
a smaller academically affiliated Veteran’s Affairs medical
center, respectively, but the number of doses administered
was similar at both sites (10). The variation in the number of
pethidine doses prescribed to patients treated in hospitals
with different accreditation levels may reflect the different
severity of diseases that required different strategies to
manage pain. Alternatively, ordering pethidine was also
found to be associated with physician specialty, hospital
location, patient race, insurance coverage, and physician
gender (2), which might also account for the observed
variations in pethidine use among geographic and medical
institutions in Taiwan.
We were not surprised by the increased proportion of
pethidine prescriptions in patients with cancer diagnoses
together with operations, which is also consistent with
previous findings (29). Previous studies reported that after
surgery, patients with cancer were more frequently treated
with analgesics than other patients (29). Furthermore, a
cancer diagnosis was found to be associated with greater
access to and use intensity of all analgesics classes (32).
Physicians do not appear hesitant to prescribe higher
amounts of opioid analgesics to individuals with cancer
diagnoses (33). Jarlbaek et al. (34) analyzed the changes in
opioid use from 1994 to 1998 in an entire cohort of cancer
patients (n= 24,190) in a Danish county. The results indicated
that the overall consumption of opioids increased from 20 kg
to 37 kg oral morphine equivalents (omeq) per year, the
average consumption increased from 7.6 to 10.7 g omeq/
opioid user/year, the annual proportion of users increased
from 17% to 20%, and the proportion of patients who were
alive two years after their first opioid prescription increased
from 38% to 55%. The results also indicate that 14% of the
population’s opioid users were cancer patients and that they
consumed 23% of the total opioids from 1993 to 1997.
Our findings demonstrate that a large proportion of
pethidine was prescribed to non-operation patients without
cancer diagnoses. The indications for pethidine use docu-
mented by emergency departments included abdominal
pain, back pain, biliary pain, chest pain, migraine/headache,
pancreatitis, renal colic, trauma/fracture, and morphine
allergy (26), which were all non-cancer diagnoses.
Nevertheless, our data showed that 10% of the total pethidine
prescriptions were found in cancer diagnoses without
operations. Therefore, there was a potential for improper
use of pethidine in non-operation cancer patients in Taiwan,
which affirms the need for further evaluation of the
appropriateness of pethidine prescriptions in non-operation
cancer patients to avoid adverse events from such use.
This study has the following strengths. First, it is
population based and includes all eligible pethidine users
in Taiwan during the study period. Therefore, the data are
highly representative and less likely to have selection bias.
Second, the study sample was collected from the NHI
database, which makes it possible to cover all pethidine
claims of individual patients with little likelihood of non-
response from the study subjects. Finally, the advantage of
using insurance claim datasets in clinical research is the ease
of access to longitudinal records of pethidine use in a large
sample of geographically dispersed patients (35).
Despite the above strengths, there are several limitations
in our study. First, the data contain no information on
compliance with prescription drugs in outpatient settings,
which could entail a degree of pethidine use misclassifica-
tion in this study. However, there is no evidence showing
that medication compliance varies with secular years, which
provides reassurance that the potential pethidine use
misclassification should not have a great effect on the
secular trends reported in this study. Second, although we
used the ICD-9-CM procedure codes to determine whether a
pethidine user had an operation, we were unable to
differentiate between acute and chronic pain associated
with the operation.
In conclusion, the prevalence of pethidine users and
prescriptions steadily decreased from 2002 to 2007 and so
did the DDD/1,000 inhabitants/day. Nevertheless, our data
show that the number and proportion of pethidine
prescriptions increased in certain subgroups, including
elderly patients, rural residents, patients with cancer
diagnoses who had operations and patients from regional
hospitals/clinics and outpatient/emergency settings. We
suggest further investigation of the appropriateness of
prescribing pethidine to these patients.
ACKNOWLEDGMENTS
This study was supported by grants from the National Bureau of
Controlled Drugs, the Department of Health, Taiwan (DOH98-NNB-
1031), and the National Science Council (NSC100-2314-B-006 -052).
AUTHOR CONTRIBUTIONS
Pan HH, Li CY, Wang JO and Lin TC conceived and designed the study
and were responsible for the data acquisition, analysis and interpretation.
Ho ST and Wang KY contributed equally to this work and were
Pethidine use in Taiwan
Pan HH et al.
CLINICS 2012;67(7):749-755
754
responsible for drafting the article and revising it critically for important
intellectual content. All authors approved the final version of the
manuscript.
REFERENCES
1. Costantini R, Affaitati G, Fabrizio A, Giamberardino MA. Controlling
pain in the post-operative setting. Int J Clin Pharmacol Ther.
2011;49(2):116-27.
2. Panda M, Desbiens N, Doshi N, Sheldon S. Determinants of prescribing
meperidine compared to morphine in hospitalized patients. Pain. 2004;
110(1-2):337-42, http://dx.doi.org/10.1016/j.pain.2004.04.016.
3. Latta KS, Ginsberg B, Barkin RL. Meperidine: a critical review. Am J Ther.
2002;9(1):53-68, http://dx.doi.org/10.1097/00045391-200201000-00010.
4. Todd M. Meperidine and the management of pain: what you need to
know. Lippincotts Case Manag. 2004;9(5):241-2.
5. Vermeulen LC, Bollinger KA, Antonopoulos J, Meek PD, Goshman LM,
Ploetz PA. Multifaceted approach to medication use policy development:
the restriction of meperidine. Pharm Pract Manag Q. 1997;16(4):66-75.
6. Kredo T, Onia R. Pethidine–does familiarity or evidence perpetuate its
use? S Afr Med J. 2005;95(2):100-1.
7. Thompson DR. Narcotic analgesic effects on the sphincter of Oddi: a
review of the data and therapeutic implications in treating pancreatitis.
Am J Gastroenterol. 2001;96(4):1266-72, http://dx.doi.org/10.1111/j.
1572-0241.2001.03536.x.
8. American Pain Society Quality of Care Committee. Quality improvement
guidelines for the treatment of acute pain and cancer pain. American
Pain Society Quality of Care Committee. JAMA. 1995;274(22):1874-80.
9. O’Callaghan JP. Evolution of a rational use of opioids in chronic pain.
Eur J Pain. 2001;5(Suppl A):21-6, http://dx.doi.org/10.1053/eujp.2001.0275.
10. Kornitzer BS, Manace LC, Fischberg DJ, Leipzig RM. Prevalence of
meperidine use in older surgical patients. Arch Surg. 2006;141(1):76-81,
http://dx.doi.org/10.1001/archsurg.141.1.76.
11. Garcia del Pozo J, Carvajal A, Viloria JM, Velasco A, Garcia del Pozo V.
Trends in the consumption of opioid analgesics in Spain. Higher increases
as fentanyl replaces morphine. Eur J Clin Pharmacol. 2008;64(4):411-5.
12. Ponizovsky AM, Marom E, Zeldin A, Cherny NI. Trends in opioid
analgesics consumption, Israel, 2000-2008. Eur J Clin Pharmacol. 2011;
67(2):165-8, http://dx.doi.org/10.1007/s00228-010-0932-0.
13. Hsu CC, Li JH. The trends of requirements in medical opioid analgesics
from 1987 through 1996 in Taiwan. Chinese Journal of Public Health.
1998;17:495-503.
14. Pellegrini JE, Paice J, Faut-Callahan M. Meperidine utilization and
compliance with Agency for Health Care Policy and Research guidelines
in a tertiary care hospital. CRNA. 1999;10(4):174-80.
15. Cepeda MS, Farrar JT, Baumgarten M, Boston R, Carr DB, Strom BL. Side
effects of opioids during short-term administration: effect of age, gender,
and race. Clin Pharmacol Ther. 2003;74(2):102-12, http://dx.doi.org/
10.1016/S0009-9236(03)00152-8.
16. Pan HH, Ho ST, Lu CC, Wang JO, Lin TC, Wang KY. Trends in the
consumption of opioid analgesics in Taiwan from 2002 to 2007: a
population-based study. J Pain Symptom Manage. 2012. (In press)
17. Food and Drug Administration, Department of Health, Taiwan.
Physician Guidelines on Clinical Use of Pethidine. 2011. Available at:
http://www.fda.gov.tw/people_laws_list.aspx?classifysn = 183.
18. Lu JFR, Hsiao WC. Does universal health insurance make health care
unaffordable? Lessons from Taiwan. Health Affairs (Millwood).
2003;22(3):77-88, http://dx.doi.org/10.1377/hlthaff.22.3.77.
19. Directorate-General Budget, Accounting and Statistics. National
Statistics of Regional Standard Classification Data. Taipei: Accounting
and Statistics; 1993.
20. WHO. WHO Collaborating Centre for Drug Statistics Methodology.
Complete ATC index 2010. Available at: http://www.whocc.no/
atcddd/.
21. Department of Statistics. Statistical yearbook of interior. 2009. Available
at: http://sowf.moi.gov.tw/stat/year/list.htm.
22. Gilson AM, Ryan KM, Joranson DE, Dahl JL. A reassessment of trends in
the medical use and abuse of opioid analgesics and implications for
diversion control: 1997-2002. J Pain Symptom Manage. 2004;28(2):176-88,
http://dx.doi.org/10.1016/j.jpainsymman.2004.01.003.
23. Joranson DE, Ryan KM, Gilson AM, Dahl JL. Trends in medical use and
abuse of opioid analgesics. JAMA. 2000;283(13):1710-4, http://
dx.doi.org/10.1001/jama.283.13.1710.
24. Hudec R, Tisonova J, Bozekova L, Foltan V. Trends in consumption of
opioid analgesics in Slovak Republic during 1998-2002. Eur J Clin
Pharmacol. 2004;60(6):445-8, http://dx.doi.org/10.1007/s00228-004-
0793-5.
25. Taylor SE, Braitberg G, Lugt J. Multifaceted education initiative
minimizes pethidine prescribing in the emergency department. Emerg
Med Australas. 2007;19(1):25-30, http://dx.doi.org/10.1111/j.1742-
6723.2006.00911.x.
26. Kaye KI, Welch SA, Graudins LV, Graudins A, Rotem T, Davis SR, et al.
Pethidine in emergency departments: promoting evidence-based pre-
scribing. Med J Aust. 2005;183(3):129-33.
27. O’Connor AB, Lang VJ, Quill TE. Eliminating analgesic meperidine use
with a supported formulary restriction. Am J Med. 2005;118(8):885-9,
http://dx.doi.org/10.1016/j.amjmed.2005.01.061.
28. Scudds RJ, Ostbye T. Pain and pain-related interference with function in
older Canadians: the Canadian Study of Health and Aging. Disabil
Rehabil. 2001;23(15):654-64, http://dx.doi.org/10.1080/0963828011
0043942.
29. Vallano A, Malouf J, Payrulet P, Banos JE. Analgesic use and pain in the
hospital settings. Eur J Clin Pharmacol. 2007;63(6):619-26, http://dx.
doi.org/10.1007/s00228-007-0303-7.
30. Lai HY, Hwang SJ, Chen YC, Chen TJ, Lin MH, Chen LK. Prevalence of
the prescribing of potentially inappropriate medications at ambulatory
care visits by elderly patients covered by the Taiwanese National Health
Insurance program. Clin Ther. 2009;31(8):1859-70, http://dx.doi.org/
10.1016/j.clinthera.2009.08.023.
31. Freye E, Levy JV. Use of opioids in the elderly – pharmacokinetic and
pharmacodynamic considerations. Anasthesiol Intensivmed Notfallmed
Schmerzther. 2004;39(9):527-37, http://dx.doi.org/10.1055/s-2004-
825883.
32. Sadowski CA, Carrie AG, Grymonpre RE, Metge CJ, St John P. Access
and intensity of use of prescription analgesics among older Manitobans.
Can J Clin Pharmacol. 2009;16(2):e322-30.
33. Morley-Forster PK, Clark AJ, Speechley M, Moulin DE. Attitudes toward
opioid use for chronic pain: a Canadian physician survey. Pain Res
Manag. 2003;8(4):189-94.
34. Jarlbaek L, Andersen M, Hallas J, Engholm G, Kragstrup J. Use of
opioids in a Danish population-based cohort of cancer patients. J Pain
Symptom Manage. 2005;29(4):336-43, http://dx.doi.org/10.1016/
j.jpainsymman.2004.07.010.
35. Jollis JG, Ancukiewicz M, DeLong ER, Pryor DB, Muhlbaier LH, Mark
DB. Discordance of databases designed for claims payment versus
clinical information systems. Implications for outcomes research. Ann
Intern Med. 1993;119(8):844-50.
Appendix- ICD-9-CM codes of diagnosis procedures classifications.
Diagnosis procedures classifications ICD-9-CM codes
Nervous system 01.1, 03.3, 05.1
Endocrine system 06.1, 07.1
Eye 08.1, 09.1, 10.2, 11.2, 12.2, 14.1,15.0, 16.2
Ear 18.1, 20.3
Nose, mouth, and pharynx 21.2, 22.1, 24.1, 25.0, 26.1, 27.2, 28.1, 29.1
Respiratory system 31.4, 33.2, 34.2
Cardiovascular system 37.2, 38.2
Hemic and lymphatic system 40.1, 41.3
Digestive system 42.2, 44.1, 45.1, 45.2, 48.2, 49.2, 50.1, 51.1, 52.1, 54.2
Urinary system 55.2, 56.3, 57.3, 58.2, 59.2
Male genital organs 60.1, 61.1, 62.1, 63.0, 64.1
Female genital organs 65.1, 66.1, 67.1,68.1,70.2,71.1
Musculoskeletal system 76.1, 78.8, 80.2, 80.3, 83.2
Integumentary system 85.1, 86.1
ICD-9-CM: International Classification of Diseases codes, 9th version Clinical Modification.
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